Finding out that your first treatment for advanced melanoma isn’t working can be discouraging. But it doesn’t mean you’re out of treatment options.

Advanced melanoma generally means stage 4 melanoma, which has spread to distant parts of the body, or stage 3 melanoma that can’t be removed with surgery.

There’s no one first-line treatment that works for everyone. In a major trial of nivolumab (Opdivo) plus ipilimumab (Yervoy), about 58 percent of people with previously untreated advanced melanoma had measurable tumor shrinkage.

This means that for 42 percent, the treatment didn’t work. Some people who initially respond may also develop treatment resistance later.

🗳️ How many lines of treatment have you used for advanced melanoma?

Haven’t started treatment yet

One line of treatment

Two lines of treatment

Three or more lines of treatment

Thanks! You've successfully submitted your vote.

Sign up to view the results!

Continue with Facebook

Continue with Google

Continue with Email

By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.

Already a member? Log In

If your first line of treatment fails, your care team will consider why treatment may have stopped working, examine how the melanoma is behaving, and review the treatment you’ve already received.

Here’s what you can expect and which treatments may come next.

What To Expect if First-Line Treatment Fails

First-line treatment can fail in different ways.

Sometimes melanoma doesn’t respond at all. Doctors call this primary resistance. Other times, treatment initially works, but the cancer later begins growing again. This is known as acquired resistance.

Cancer cells have many tactics to resist treatment. For example, they may have characteristics that make it harder for immune cells to recognize or attack them. Tumors can also change over time and find ways around a treatment that initially worked.

More Testing

Before changing treatment, your oncologist will determine whether the melanoma is truly progressing.

That’s particularly important with immunotherapy. In uncommon cases, tumors initially look larger on scans because immune cells have entered them rather than because the cancer is growing. This is called pseudoprogression.

If the cancer is progressing, your doctor may order new imaging or other tests. Your doctor may also test cancer cells for BRAF mutations if they haven’t yet been tested. Results can help determine whether targeted therapy is an option.

What Does It Mean for Your Outlook?

Progression after first-line therapy can affect your outlook because it means the cancer has resisted a treatment that might otherwise have controlled it. But it can’t predict exactly what will happen next.

Your outlook depends on factors such as where the melanoma has spread, how quickly it’s growing, your overall health, and whether another treatment works. Failure of one treatment doesn’t mean that another type of treatment won’t work.

Next Lines of Therapy if First-Line Treatment Fails

There’s no single next-line treatment that’s right for everyone. What comes next depends largely on what treatment you’ve already received and how the melanoma responded.

Another Immunotherapy Approach

If you’ve received one immunotherapy drug, your oncologist may consider another immune checkpoint inhibitor or a combination.

Checkpoint inhibitors target different signals cancer can use to suppress the immune system. For example, someone whose melanoma progresses after a PD-1 inhibitor such as pembrolizumab or nivolumab may be considered for treatment with ipilimumab, sometimes combined with nivolumab. These drugs work in different ways.

Your previous side effects matter too. If immunotherapy caused a serious immune-related reaction, your oncologist will weigh the potential benefits of more immunotherapy against the risks.

BRAF and MEK Targeted Therapy

If your melanoma has a BRAF V600 mutation and you haven’t received BRAF/MEK targeted therapy, it can be an important option after immunotherapy.

These drugs block signals melanoma cells use to grow. They’re usually given in combinations such as dabrafenib plus trametinib.

Targeted therapy can sometimes shrink melanoma relatively quickly, which may be helpful when cancer is growing rapidly or causing symptoms. However, melanoma can eventually develop resistance to these drugs.

Tumor-Infiltrating Lymphocyte Therapy

Tumor-infiltrating lymphocyte (TIL) therapy is a newer option for some people whose melanoma continues to grow despite previous treatment.

The U.S. Food and Drug Administration (FDA) approved lifileucel (Amtagvi) in 2024 for adults with unresectable or metastatic melanoma previously treated with a PD-1-blocking drug. People with BRAF V600-positive melanoma must also have tried a BRAF inhibitor, with or without a MEK inhibitor.

TIL therapy uses your own immune cells. Doctors remove a piece of tumor and collect immune cells called tumor-infiltrating lymphocytes, or TILs, from it. Large numbers of those cells are grown in a laboratory and returned to your body to help attack the melanoma.

The process is more involved than a standard immunotherapy infusion. It includes surgery to collect tumor tissue, chemotherapy before the cell infusion, the TIL infusion itself, and additional treatment to help the transferred cells grow. It’s generally performed at a specialized treatment center.

In a study of heavily pretreated advanced melanoma, about 31 percent of people had a measurable response to lifileucel. Follow-up research has found that some responses can last for years.

Surgery or Radiation Therapy

Systemic medications are the main treatment for most advanced melanoma, but surgery or radiation may help if cancer is progressing in only one or a few areas.

Radiation can also help control symptoms or treat melanoma that has spread to the brain. In some cases, these local treatments are combined with systemic therapy.

Other Treatments

Some people may have additional options based on where their melanoma is located and what treatments they’ve already received.

One example is talimogene laherparepvec (Imlygic), also called T-VEC, an altered virus injected directly into accessible melanoma tumors. Another treatment similar to T-VEC that was approved by the FDA in August 2026 is vusolimogene oderparepvec-wtpg (Tudriqev), which is given in combination with nivolumab for patients with unresectable advanced cutaneous melanoma that has progressed after a PD-1-blocking drug.

Traditional chemotherapy is another possibility, although it plays a much smaller role now that more effective treatments are available.

Your melanoma subtype can also affect your options. For example, melanoma that starts in the eye, called uveal melanoma, is treated differently from the more common cutaneous melanoma.

Planning Your Next Move

If your first treatment has stopped working, ask your oncologist whether the melanoma has definitely progressed and what options make the most sense based on your previous treatments, tumor characteristics, health, and priorities.

You may also want to ask about the goal of each treatment, possible side effects, and how quickly you need to make a decision.

Treatment for advanced melanoma has changed rapidly, and newer options such as TIL therapy have expanded what may be possible after immunotherapy stops working.

Your care team can explain the latest treatments and which may be most appropriate for you. If you’re interested in a clinical trial, they can also help you look for studies nearby you might be eligible for.